Skip to main content
KMTSKestra Medical Technologies, LtSell5.5·$24.08-4.37%

Kestra Medical Technologies, Lt (KMTS) Q2 2026 earnings — TrendMatrix coverage

BEAT · SMALLER LOSS+26.7% vs estimateEPS -$0.46 vs -$0.62 estVerdict HoldSell

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
-$0.46
Estimate
-$0.62
Surprise
+26.7%
Revenue (period 2026-07-31)
$31.0M
Score at report (before → after)
5.65.5/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Kestra Medical Technologies, Lt (KMTS) reported a narrower loss than forecast — diluted EPS of -$0.46 against the -$0.62 estimate (a 26.7% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Hold (5.6/10) to Sell at 5.5/10 after the report — the engine's score fell despite the beat.

Around the report

Coverage in the report window

  • Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Mobenzinga, 2026-09-15
  • Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarketbenzinga, 2026-09-15
  • Transcript: Kestra Medical Techs Q1 2027 Earnings Conference Callbenzinga, 2026-09-14
Current read · as of 2026-09-17

Where TrendMatrix's rating stands now

TrendMatrix currently rates KMTS Sell at 5.5/10.

4 of the last 4 quarters beat the estimate; this quarter's +26.7% surprise compares with a +23.7% four-quarter average. Next scheduled report: 2026-12-14.

What supports the rating

  • Sector modifier (Healthcare): +0.5
  • Strong earnings beat streak (4/4)

What argues against it

  • Concentration risk — Product: ASSURE WCD
  • Concentration risk — Supplier: primary suppliers
  • Thin upside margin: 9.4%

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$24.08
Price target
$26.35
Stop
$22.39
Upside to target
+9.4%
Reward-to-risk
0.8:1

Risk check: trading volume is running 2.4× its average — elevated turnover around the report window.

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare context

KMTS at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Medical Instruments & Supplies
Market cap
$1.50B
P/E (fwd)
-12.3
52-week range
$17.34$30.00
Off 52-week high
19.7%
RSI (14)
37
Volume vs avg
2.41×
Score today
5.5/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks KMTS Earnings Q2 2026 earnings